Introduction
Patients and methods
Data collection of clinical information
QOL assessment using menopause-specific quality of life questionnaire (MENQOL)
Breast cancer-specific QOL assessment using functional assessment of Cancer therapy-breast (FACT-B + 4)
Sample size estimation
Statistical analysis
Results
Patients’ background demographics and breast cancer characteristics
No. of patients | % | |
---|---|---|
Age at time of breast cancer diagnosis | ||
≤ 35 | 42 | 15 |
36–40 | 81 | 28.9 |
41–45 | 157 | 56.1 |
Age at study entry | ||
≤ 35 | 8 | 2.9 |
36–40 | 26 | 9.2 |
41–45 | 76 | 27.1 |
46–50 | 146 | 52.1 |
> 50 | 23 | 8.6 |
Education | ||
Primary | 47 | 16.9 |
Secondary | 187 | 67.0 |
Tertiary and higher qualification | 45 | 16.2 |
Marital Status | ||
Single | 43 | 15.4 |
Married Partner | 216 | 77.1 |
Divorced | 15 | 5.4 |
Widowed | 6 | 2.1 |
Family income* | ||
< HK$5000 | 27 | 9.6 |
HK$5000-25,000 | 150 | 53.6 |
> HK$25,000 | 103 | 36.8 |
BMI at study entry (kg/m2) [25] | ||
< 18.5 (Underweight) | 11 | 3.9 |
18.5–22.9 (Normal) | 123 | 44.0 |
23.0–24.9 (Overweight) | 62 | 22.1 |
> 25 (Obese) | 84 | 30.0 |
Staging | ||
I | 88 | 31.4 |
II | 165 | 58.9 |
III | 27 | 9.6 |
Hormonal receptor | ||
ER positive | 203 | 72.5 |
PR positive | 187 | 66.8 |
HER overexpression | 47 | 16.8 |
Breast surgery: | ||
Lumpectomy | 95 | 33.9 |
Mastectomy | 185 | 66.1 |
Axillary nodal dissection | 276 | 98.6 |
Adjuvant radiotherapy | 186 | 66.4 |
Adjuvant chemotherapy regimen: | ||
Taxane-containing | 79 | 28.2 |
Non-taxane-containing | 201 | 71.8 |
Adjuvant chemotherapy lasting longer than 64 days | 191 | 68.2 |
Time since last adjuvant treatment** | ||
3 to < 5 years | 160 | 57.1 |
5 to < 10 years | 120 | 42.9 |
Ever received adjuvant tamoxifen | 214 | 76.4 |
On adjuvant tamoxifen at study entry | 115 | 41.1 |
Adjuvant targeted therapy with trastuzumab | 8 | 2.9 |
Utilization of traditional Chinese medicine since diagnosis | 83 | 29.6 |
Menopausal status at study entry | ||
Premenopausal | 112 | 40 |
Peri/Post- menopausal | 168 | 60 |
Analysis for MENQOL at study entry
MENQOL domain | Mean (SD) | No. of patients with scores < mean (%) | No. of patients with scores >/= mean (%) |
---|---|---|---|
Vasomotor | 2.51 (1.70) | 177 (63.2) | 103 (36.8) |
Psychosoical | 2.76 (1.41) | 161 (57.5%) | 119 (42.5%) |
Physical | 2.82 (1.10) | 150 (53.6%) | 130 (46.4%) |
Sexual | 2.61 (1.90) | 173 (61.8%) | 107 (38.2%) |
vasomotor domain | psychosocial domain | physical domain | sexual domain | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Mean score | SD | p | Mean score | SD | p | Mean score | SD | p | Mean score | SD | p | |
Overall population | 2.51 | 1.70 | – | 2.76 | 1.41 | – | 2.82 | 1.10 | – | 2.61 | 1.90 | – |
No. of patients with scores >/= mean (%) | 103 (36.8) | 119 (42.5) | 130 (46.4) | 107 (38.2) | ||||||||
Age at time of study entry | 0.1227 | 0.1036 | 0.6317 | 0.2397 | ||||||||
≤ 40 | 2.25 | 1.69 | 2.28 | 1.13 | 2.73 | 1.14 | 1.99 | 1.53 | ||||
41–45 | 2.46 | 1.73 | 2.93 | 1.51 | 2.95 | 1.20 | 2.65 | 1.84 | ||||
46–50 | 2.70 | 1.75 | 2.81 | 1.41 | 2.78 | 1.03 | 2.70 | 2.02 | ||||
> 50 | 1.90 | 1.01 | 2.48 | 1.34 | 2.74 | 1.13 | 2.81 | 1.70 | ||||
BMI at study entry | 0.8753 | 0.3717 | 0.0162 | 0.2760 | ||||||||
Underweight or Normal | 2.53 | 1.73 | 2.68 | 1.37 | 2.65 | 1.07 | 2.74 | 1.93 | ||||
Overweight or Obese | 2.50 | 1.67 | 2.83 | 1.44 | 2.97 | 1.11 | 2.49 | 1.87 | ||||
Breast surgery: | 0.9321 | 0.6877 | 0.5563 | 0.1375 | ||||||||
Lumpectomy | 2.52 | 1.69 | 2.71 | 1.42 | 2.76 | 1.05 | 2.37 | 1.64 | ||||
Mastectomy | 2.50 | 1.70 | 2.78 | 1.41 | 2.84 | 1.13 | 2.73 | 2.01 | ||||
Axillary nodal dissection | 0.6127 | 0.3630 | 0.7797 | 0.1500 | ||||||||
Yes | 2.52 | 1.70 | 2.75 | 1.41 | 2.81 | 1.10 | 2.63 | 1.90 | ||||
No | 2.08 | 1.95 | 3.39 | 0.88 | 2.97 | 0.61 | 1.25 | 0.50 | ||||
Adjuvant radiotherapy | 0.7467 | 0.3781 | 0.7246 | 0.9861 | ||||||||
Yes | 2.53 | 1.58 | 2.70 | 1.36 | 2.83 | 1.05 | 2.61 | 1.87 | ||||
No | 2.46 | 1.76 | 2.86 | 1.50 | 2.78 | 1.18 | 2.61 | 0.50 | ||||
Adjuvant chemotherapy regimen: | 0.0140 | 0.9373 | 0.7131 | 0.9094 | ||||||||
Taxane-containing | 2.91 | 1.89 | 2.75 | 1.26 | 2.85 | 1.02 | 2.59 | 1.84 | ||||
Non-taxane-containing | 2.35 | 1.59 | 2.76 | 1.46 | 2.80 | 1.13 | 2.62 | 1.92 | ||||
Duration of adjuvant chemotherapy | 0.2232 | 0.3966 | 0.8625 | 0.8946 | ||||||||
< =64 days | 2.33 | 1.75 | 2.86 | 1.51 | 2.80 | 1.14 | 2.63 | 2.09 | ||||
> 64 days | 2.60 | 1.57 | 2.71 | 1.36 | 2.82 | 1.08 | 2.60 | 1.80 | ||||
Time since last adjuvant treatment* | 0.2568 | 0.4249 | 0.3966 | 0.3051 | ||||||||
3 to < 5 years | 2.61 | 1.69 | 2.70 | 1.36 | 2.77 | 1.08 | 2.51 | 1.85 | ||||
5 to < 10 years | 2.38 | 1.70 | 2.83 | 1.47 | 2.88 | 1.13 | 2.74 | 1.96 | ||||
Ever received adjuvant tamoxifen | 0.8659 | 0.8076 | 0.8320 | 0.7338 | ||||||||
Yes | 2.52 | 1.76 | 2.77 | 1.38 | 2.82 | 1.12 | 2.59 | 1.88 | ||||
No | 2.48 | 1.50 | 2.72 | 1.52 | 2.79 | 1.03 | 2.68 | 1.98 | ||||
On adjuvant tamoxifen at study entry | 0.0479 | 0.7057 | 0.9349 | 0.6175 | ||||||||
Yes | 2.75 | 1.84 | 2.79 | 1.32 | 2.82 | 1.10 | 2.54 | 1.86 | ||||
No | 2.34 | 1.57 | 2.73 | 1.47 | 2.81 | 1.10 | 2.65 | 1.93 | ||||
Adjuvant targeted therapy with trastuzumab | 0.7117 | 0.8083 | 0.9443 | 0.7262 | ||||||||
Yes | 2.29 | 1.20 | 2.88 | 1.56 | 2.79 | 0.72 | 2.38 | 1.86 | ||||
No | 2.52 | 1.71 | 2.75 | 1.41 | 2.82 | 1.11 | 2.61 | 1.90 | ||||
Utilization of traditional Chinese medicine since diagnosis | 0.0054 | 0.0028 | 0.0052 | 0.3732 | ||||||||
Yes | 2.94 | 1.80 | 3.14 | 1.55 | 3.10 | 1.19 | 2.76 | 1.95 | ||||
No | 2.33 | 1.62 | 2.59 | 1.31 | 2.70 | 1.04 | 2.54 | 1.88 | ||||
Menopausal status at study entry | 0.2079 | 0.7446 | 0.9338 | 0.0229 | ||||||||
Premenopausal | 2.35 | 1.67 | 2.72 | 1.49 | 2.82 | 1.16 | 2.29 | 1.64 | ||||
Peri/Post- menopausal | 2.62 | 1.71 | 2.78 | 1.35 | 2.81 | 1.06 | 2.82 | 2.03 |
Analysis on FACT-B + 4 score in association with MENQOL domain scores at study entry
FACT-B Subscales | Overall population | MENQOL vasomotor domain | MENQOL psychosocial domain | MENQOL physical domain | MENQOL sexual domain | ||||
---|---|---|---|---|---|---|---|---|---|
< Mean | >/= Mean | < Mean | >/= Mean | < Mean | >/= Mean | < Mean | >/= Mean | ||
Physical well-being | 23.4 | 24.5 | 21.5 | 25.0 | 21.2 | 25.2 | 21.3 | 23.8 | 22.6 |
SD | 4.14 | 3.73 | 4.19 | 3.11 | 4.35 | 2.88 | 4.36 | 4.10 | 4.10 |
p-value | – | < 0.0001 | < 0.0001 | < 0.0001 | 0.0152 | ||||
Functional well-being | 19.9 | 20.5 | 18.8 | 21.8 | 17.4 | 21.5 | 18.0 | 20.9 | 18.3 |
SD | 5.45 | 5.67 | 4.87 | 5.22 | 4.71 | 5.26 | 5.06 | 5.02 | 5.77 |
p-value | – | 0.0100 | < 0.0001 | < 0.0001 | 0.0001 | ||||
Psychosocial well-being | 19.4 | 19.9 | 18.6 | 20.6 | 17.7 | 20.7 | 17.9 | 20.0 | 18.5 |
SD | 6.03 | 5.98 | 6.08 | 6.05 | 5.61 | 5.80 | 5.98 | 5.99 | 6.02 |
p-value | 0.1034 | < 0.0001 | 0.0001 | 0.0479 | |||||
Emotional well-being | 17.7 | 18.4 | 16.5 | 19.3 | 15.5 | 19.1 | 16.0 | 18.5 | 16.3 |
SD | 4.19 | 3.82 | 4.54 | 3.39 | 4.16 | 3.49 | 4.32 | 4.09 | 4.02 |
p-value | – | 0.002 | < 0.0001 | < 0.0001 | < 0.0001 | ||||
BCS score | 22.3 | 23.7 | 19.8 | 24.3 | 19.5 | 24.1 | 20.1 | 23.2 | 20.6 |
SD | 5.26 | 5.16 | 4.42 | 4.85 | 4.44 | 5.28 | 4.33 | 5.07 | 5.19 |
p-value | – | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 | ||||
Arm subscale | 14.9 | 15.7 | 13.5 | 16.2 | 13.1 | 16.4 | 13.2 | 15.5 | 13.9 |
SD | 3.92 | 3.68 | 3.95 | 3.41 | 3.86 | 3.23 | 3.94 | 3.83 | 3.87 |
p-value | – | < 0.0001 | < 0.0001 | < 0.0001 | 0.0005 | ||||
FACT-B total score | 102.6 | 107.0 | 95.2 | 111.1 | 91.2 | 110.7 | 93.3 | 106.4 | 96.5 |
SD | 18.78 | 18.28 | 17.30 | 15.73 | 16.44 | 16.20 | 17.21 | 17.92 | 18.58 |
p-value | – | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 |